Substance / Medication

Monoamine oxidase inhibitor

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

No related conditions have been mapped yet. Condition-intervention linkages are derived from SNOMED CT relationships and will expand as the knowledge graph grows.

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Safety of Ketamine Augmentation to Monoamine Oxidase Inhibitors in Treatment-Resistant Depression: A Systematic Literature Review and Case Series.
Veraart Jolien K E, Smith-Apeldoorn Sanne Y, Kutscher Mats et al. · J Clin Psychiatry · 2022
PMID: 36300995Meta-Analysis
Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: A systematic review and network meta-analysis.
Suchting Robert, Tirumalajaru Vaishali, Gareeb Rida et al. · J Affect Disord · 2021
PMID: 33601690Meta-Analysis
Intoxications with the monoamine oxidase inhibitor tranylcypromine: an analysis of fatal and non-fatal events.
Gahr Maximilian, Schönfeldt-Lecuona Carlos, Kölle Markus A et al. · Eur Neuropsychopharmacol · 2013
PMID: 23791433Meta-Analysis
Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome.
Tort Sera, Urrútia Gerard, Nishishinya María Betina et al. · Cochrane Database Syst Rev · 2012
PMID: 22513976Meta-AnalysisFull text (PMC)
Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer.
Gross Mitchell E, Agus David B, Dorff Tanya B et al. · Prostate Cancer Prostatic Dis · 2021
PMID: 32123315TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Substance with monoamine oxidase inhibitor mechanism of action (substance)
SNOMED CT
373281001
UMLS CUI
C0026457

Clinical Data

This intervention maps to 0 entities in the Ltrl knowledge graph.

0
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.